Inhibitory effects of the new bombesin receptor antagonist RC-3095 on the luteinizing hormone release in rats

J. Pinski, T. Yano, Andrew V Schally

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The effects of bombesin receptor antagonist RC-3095 and gastrin-releasing peptide [GRP (14-27)] on basal luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone levels, as well as on the release of LH and FSH in response to LH-releasing hormone, were studied in normal and castrated male rats. We also examined the release of LH and FSH after intracerebroventricular injection of RC-3095 under different types of anesthesia (urethane, sodium pentobarbital, Metofane). Following injection of 10 μg RC-3095 into the lateral brain ventricle, serum LH levels were rapidly and significantly (p < 0.001) lowered. This effect lasted for at least 60 min and was not affected by the type of anesthetic used. Serum FSH levels were not affected by intracerebroventricular administration of RC-3095 or GRP (14-27), indicating different central control mechanisms between LH and FSH release. The suppressive effect of RC-3095 on LH release could be completely prevented by prior intracerebroventricular administration of GRP (14-27) at a dose of 1 μg, but intravenous administration of either peptide RC-3095 or GRP (14-27) did not change the basal levels of LH, FSH, and testosterone. The pituitary LH response to LH-releasing hormone was also not modified by intravenous administration of RC-3095. These results indicate that bombesin-like peptides might be involved in control of LH release from the pituitary by an action on the CNS which is mediated by specific bombesin receptors.

Original languageEnglish
Pages (from-to)831-837
Number of pages7
JournalNeuroendocrinology
Volume56
Issue number6
StatePublished - Dec 1 1992
Externally publishedYes

Fingerprint

Bombesin Receptors
Luteinizing Hormone
Follicle Stimulating Hormone
Gonadotropin-Releasing Hormone
Intravenous Administration
Testosterone
Tpi(6)-Leu(13)-psi(CH2NH)-Leu(14)-bombesin (6-14)
Bombesin
Peptides
Injections
Pituitary Hormones
Lateral Ventricles
Urethane
Pentobarbital
Serum
Anesthetics
Anesthesia

Keywords

  • Bombesin receptor antagonist
  • Follicle-stimulating hormone
  • Luteinizing hormone

ASJC Scopus subject areas

  • Endocrinology
  • Neuroscience(all)

Cite this

Inhibitory effects of the new bombesin receptor antagonist RC-3095 on the luteinizing hormone release in rats. / Pinski, J.; Yano, T.; Schally, Andrew V.

In: Neuroendocrinology, Vol. 56, No. 6, 01.12.1992, p. 831-837.

Research output: Contribution to journalArticle

@article{ded9a0a694354885a4aae2fd0f6823e2,
title = "Inhibitory effects of the new bombesin receptor antagonist RC-3095 on the luteinizing hormone release in rats",
abstract = "The effects of bombesin receptor antagonist RC-3095 and gastrin-releasing peptide [GRP (14-27)] on basal luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone levels, as well as on the release of LH and FSH in response to LH-releasing hormone, were studied in normal and castrated male rats. We also examined the release of LH and FSH after intracerebroventricular injection of RC-3095 under different types of anesthesia (urethane, sodium pentobarbital, Metofane). Following injection of 10 μg RC-3095 into the lateral brain ventricle, serum LH levels were rapidly and significantly (p < 0.001) lowered. This effect lasted for at least 60 min and was not affected by the type of anesthetic used. Serum FSH levels were not affected by intracerebroventricular administration of RC-3095 or GRP (14-27), indicating different central control mechanisms between LH and FSH release. The suppressive effect of RC-3095 on LH release could be completely prevented by prior intracerebroventricular administration of GRP (14-27) at a dose of 1 μg, but intravenous administration of either peptide RC-3095 or GRP (14-27) did not change the basal levels of LH, FSH, and testosterone. The pituitary LH response to LH-releasing hormone was also not modified by intravenous administration of RC-3095. These results indicate that bombesin-like peptides might be involved in control of LH release from the pituitary by an action on the CNS which is mediated by specific bombesin receptors.",
keywords = "Bombesin receptor antagonist, Follicle-stimulating hormone, Luteinizing hormone",
author = "J. Pinski and T. Yano and Schally, {Andrew V}",
year = "1992",
month = "12",
day = "1",
language = "English",
volume = "56",
pages = "831--837",
journal = "Neuroendocrinology",
issn = "0028-3835",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Inhibitory effects of the new bombesin receptor antagonist RC-3095 on the luteinizing hormone release in rats

AU - Pinski, J.

AU - Yano, T.

AU - Schally, Andrew V

PY - 1992/12/1

Y1 - 1992/12/1

N2 - The effects of bombesin receptor antagonist RC-3095 and gastrin-releasing peptide [GRP (14-27)] on basal luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone levels, as well as on the release of LH and FSH in response to LH-releasing hormone, were studied in normal and castrated male rats. We also examined the release of LH and FSH after intracerebroventricular injection of RC-3095 under different types of anesthesia (urethane, sodium pentobarbital, Metofane). Following injection of 10 μg RC-3095 into the lateral brain ventricle, serum LH levels were rapidly and significantly (p < 0.001) lowered. This effect lasted for at least 60 min and was not affected by the type of anesthetic used. Serum FSH levels were not affected by intracerebroventricular administration of RC-3095 or GRP (14-27), indicating different central control mechanisms between LH and FSH release. The suppressive effect of RC-3095 on LH release could be completely prevented by prior intracerebroventricular administration of GRP (14-27) at a dose of 1 μg, but intravenous administration of either peptide RC-3095 or GRP (14-27) did not change the basal levels of LH, FSH, and testosterone. The pituitary LH response to LH-releasing hormone was also not modified by intravenous administration of RC-3095. These results indicate that bombesin-like peptides might be involved in control of LH release from the pituitary by an action on the CNS which is mediated by specific bombesin receptors.

AB - The effects of bombesin receptor antagonist RC-3095 and gastrin-releasing peptide [GRP (14-27)] on basal luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone levels, as well as on the release of LH and FSH in response to LH-releasing hormone, were studied in normal and castrated male rats. We also examined the release of LH and FSH after intracerebroventricular injection of RC-3095 under different types of anesthesia (urethane, sodium pentobarbital, Metofane). Following injection of 10 μg RC-3095 into the lateral brain ventricle, serum LH levels were rapidly and significantly (p < 0.001) lowered. This effect lasted for at least 60 min and was not affected by the type of anesthetic used. Serum FSH levels were not affected by intracerebroventricular administration of RC-3095 or GRP (14-27), indicating different central control mechanisms between LH and FSH release. The suppressive effect of RC-3095 on LH release could be completely prevented by prior intracerebroventricular administration of GRP (14-27) at a dose of 1 μg, but intravenous administration of either peptide RC-3095 or GRP (14-27) did not change the basal levels of LH, FSH, and testosterone. The pituitary LH response to LH-releasing hormone was also not modified by intravenous administration of RC-3095. These results indicate that bombesin-like peptides might be involved in control of LH release from the pituitary by an action on the CNS which is mediated by specific bombesin receptors.

KW - Bombesin receptor antagonist

KW - Follicle-stimulating hormone

KW - Luteinizing hormone

UR - http://www.scopus.com/inward/record.url?scp=0027078168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027078168&partnerID=8YFLogxK

M3 - Article

VL - 56

SP - 831

EP - 837

JO - Neuroendocrinology

JF - Neuroendocrinology

SN - 0028-3835

IS - 6

ER -